Advertisement

The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?

      Highlights

      • It is possible to prevent progression to type 2 diabetes in high risk individuals.
      • Risk of complications from type 2 diabetes can be reduced by good early control.
      • The Berlin Declaration proposes simple policies to target these issues.
      • It is hoped that this will empower people to take action and improve outcomes.
      • Primary care physicians have a key role in implementing the Berlin Declaration.

      Abstract

      Diabetes is epidemic worldwide and places a huge burden on healthcare systems. The majority of the cost of type 2 diabetes (T2D) is related to hospitalization and the management of complications, and these also have a negative impact on the individual’s quality of life. The Berlin Declaration is a global call for early action for the identification of high risk individuals, prevention of T2D and the prevention of complications in those with T2D, through prevention, early detection, early control and early access to the right multidisciplinary interventions. This should empower people to take action to prevent T2D and its complications.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Primary Care Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. International Diabetes Federation, IDF Diabetes Atlas – 8th Edition, 2017. http://www.diabetesatlas.org/component/attachments/?task=download&id=254. (Last accessed 3 January 2018).

      2. N.I.o.H. US Department of Health and Human Services, and National Institute of Diabetes and Digestive Kidney Disease, Diabetes Prevention Program (DPP), 2003. www.niddk.nih.gov/aboutniddk/researchareas/diabetes/diabetes-preventionprogram-dpp/Documents/DPP_508.pdf. (Last accessed 3 March 2017).

        • Dunkley A.J.
        • Bodicoat D.H.
        • Greaves C.J.
        • Russell C.
        • Yates T.
        • Davies M.J.
        • Khunti K.
        Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis.
        Diabetes Care. 2014; 37: 922-933
        • Barry E.
        • Roberts S.
        • Oke J.
        • Vijayaraghavan S.
        • Normansell R.
        • Greenhalgh T.
        Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions.
        Bmj. 2017; 356i6538
        • Ryden L.
        • Grant P.J.
        • Anker S.D.
        • Berne C.
        • Cosentino F.
        • Danchin N.
        • Deaton C.
        • Escaned J.
        • Hammes H.P.
        • Huikuri H.
        • Marre M.
        • Marx N.
        • Mellbin L.
        • Ostergren J.
        • Patrono C.
        • Seferovic P.
        • Uva M.S.
        • Taskinen M.R.
        • Tendera M.
        • Tuomilehto J.
        • Valensi P.
        • Zamorano J.L.
        • Achenbach S.
        • Baumgartner H.
        • Bax J.J.
        • Bueno H.
        • Dean V.
        • Erol C.
        • Fagard R.
        • Ferrari R.
        • Hasdai D.
        • Hoes A.W.
        • Kirchhof P.
        • Knuuti J.
        • Kolh P.
        • Lancellotti P.
        • Linhart A.
        • Nihoyannopoulos P.
        • Piepoli M.F.
        • Ponikowski P.
        • Sirnes P.A.
        • Tamargo J.L.
        • Torbicki A.
        • Wijns W.
        • Windecker S.
        • De Backer G.
        • Ezquerra E.A.
        • Avogaro A.
        • Badimon L.
        • Baranova E.
        • Betteridge J.
        • Ceriello A.
        • Funck-Brentano C.
        • Gulba D.C.
        • Kjekshus J.K.
        • Lev E.
        • Mueller C.
        • Neyses L.
        • Nilsson P.M.
        • Perk J.
        • Reiner Z.
        • Sattar N.
        • Schachinger V.
        • Scheen A.
        • Schirmer H.
        • Stromberg A.
        • Sudzhaeva S.
        • Viigimaa M.
        • Vlachopoulos C.
        • Xuereb R.G.
        ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).
        Eur Heart J. 2013; 34: 3035-3087
        • Paneni F.
        • Luscher T.F.
        Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes.
        Am J Cardiol. 2017; 120: S17-S27
        • American Diabetes Association
        The Cost of Diabetes.
        2015 (http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html. (Last accessed 6 June 2017))
      3. Economic costs of diabetes in the U.S. in 2012.
        Diabetes Care. 2013; 36: 1033-1046
        • American Diabetes Association
        Standards of medical care in diabetes – 2017.
        Diabetes Care. 2017; 40: S1-S135
        • Gaede P.
        • Oellgaard J.
        • Carstensen B.
        • Rossing P.
        • Lund-Andersen H.
        • Parving H.H.
        • Pedersen O.
        Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
        Diabetologia. 2016; 59: 2298-2307
        • Hollingworth S.A.
        • Donald M.
        • Zhang J.
        • Vaikuntam B.P.
        • Russell A.
        • Jackson C.
        Impact of a general practitioner-led integrated model of care on the cost of potentially preventable diabetes-related hospitalisations.
        Prim Care Diabetes. 2017; 11: 344-347
        • Gong Q.
        • Gregg E.W.
        • Wang J.
        • An Y.
        • Zhang P.
        • Yang W.
        • Li H.
        • Jiang Y.
        • Shuai Y.
        • Zhang B.
        • Zhang J.
        • Gerzoff R.B.
        • Roglic G.
        • Hu Y.
        • Li G.
        • Bennett P.H.
        Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study.
        Diabetologia. 2011; 54: 300-307
        • Briggs A.H.
        • Bhatt D.L.
        • Scirica B.M.
        • Raz I.
        • Johnston K.M.
        • Szabo S.M.
        • Bergenheim K.
        • Mukherjee J.
        • Hirshberg B.
        • Mosenzon O.
        Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: a subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.
        Diabetes Res Clin Pract. 2017; 130: 24-33
        • Trikkalinou A.
        • Papazafiropoulou A.K.
        • Melidonis A.
        Type 2 diabetes and quality of life.
        World J Diabetes. 2017; 8: 120-129
        • The Berlin Declaration Steering Group
        • The Berlin Declaration
        A collective ambition for policy change to drive early action in type 2 diabetes.
        2016 (http://www.idf.org/sites/default/files/Berlin-Declaration-2016.pdf. (Last accessed 3 March 2017))
        • Global Diabetes Policy Forum
        Early Acton Summary Report.
        2016 (http://www.earlyactionberlin.com/. (Last accessed 4 September 2017))
        • Kalra S.
        • Lauritzen T.
        • Sharmanov T.
        • Akanov Z.
        • Al Awadi F.
        • Das A.K.
        • Lopez C.E.
        • Medea G.
        • Oh P.
        • Samoilova Y.
        • Shestakova M.
        • Netto P.
        • Cos X.
        • Farghaly M.
        • Du X.
        Alma-Ata to Berlin: diabetes prevention and treatment to achieve healthy living.
        Diabet Med. 2017; 34: 1169-1170
      4. Diabetes care and research in Europe: the Saint Vincent declaration.
        Diabet Med. 1990; 7: 360
        • World Heart Federation
        Global CVD Roadmaps.
        2017
        • Yusuf S.
        • Perel P.
        • Wood D.
        • Narula J.
        Reducing cardiovascular disease globally: the World Heart Federation’s roadmaps.
        Glob Heart. 2015; 10: 93-95
        • Institute for Work & Health
        What Researchers Mean By… Primary, Secondary and Tertiary Prevention.
        2015 (http://www.iwh.on.ca/system/files/at-work/at_work_80.pdf. (Last accessed 3 March 2017))
        • Waugh N.
        • Scotland G.
        • McNamee P.
        • Gillett M.
        • Brennan A.
        • Goyder E.
        • Williams R.
        • John A.
        Screening for type 2 diabetes: literature review and economic modelling.
        Health Technol Assess. 2007; 11 (iii–iv, ix–xi, 1–125)
        • Messina J.
        • Campbell S.
        • Morris R.
        • Eyles E.
        • Sanders C.
        A narrative systematic review of factors affecting diabetes prevention in primary care settings.
        PLoS One. 2017; 12e0177699
        • Tuomilehto J.
        • Schwarz P.E.
        Preventing diabetes early versus late preventive interventions.
        Diabetes Care. 2016; 39: S115-–S120
        • Rice K.
        • Te Hiwi B.
        • Zwarenstein M.
        • Lavallee B.
        • Barre D.E.
        • Harris S.B.
        Best practices for the prevention and management of diabetes and obesity-related chronic disease among indigenous peoples in Canada: a review.
        Can J Diabetes. 2016; 40: 216-225
        • Herbozo S.
        • Flynn P.M.
        • Stevens S.D.
        • Betancourt H.
        Dietary adherence, glycemic control, and psychological factors associated with binge eating among indigenous and non-indigenous Chileans with type 2 diabetes.
        Int J Behav Med. 2015; 22: 792-798
        • Clifford A.
        • Jackson Pulver L.
        • Richmond R.
        • Shakeshaft A.
        • Ivers R.
        Disseminating best-evidence health-care to Indigenous health-care settings and programs in Australia: identifying the gaps.
        Health Promot Int. 2009; 24: 404-415
        • Mann J.F.E.
        • Orsted D.D.
        • Brown-Frandsen K.
        • Marso S.P.
        • Poulter N.R.
        • Rasmussen S.
        • Tornoe K.
        • Zinman B.
        • Buse J.B.
        Liraglutide and renal outcomes inin type 2 diabetes.
        N Engl J Med. 2017; 377: 839-848
        • Marso S.P.
        • Daniels G.H.
        • Brown-Frandsen K.
        • Kristensen P.
        • Mann J.F.
        • Nauck M.A.
        • Nissen S.E.
        • Pocock S.
        • Poulter N.R.
        • Ravn L.S.
        • Steinberg W.M.
        • Stockner M.
        • Zinman B.
        • Bergenstal R.M.
        • Buse J.B.
        Liraglutide and cardiovascular in type 2 diabetes.
        N Engl J Med. 2016; 375: 311-322
        • Kosiborod M.
        • Cavender M.A.
        • Fu A.Z.
        • Wilding J.P.
        • Khunti K.
        • Holl R.W.
        • Norhammar A.
        • Birkeland K.I.
        • Jorgensen M.E.
        • Thuresson M.
        • Arya N.
        • Bodegard J.
        • Hammar N.
        • Fenici P.
        Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors).
        Circulation. 2017; 136: 249-259
        • Birkeland M.E.
        • Jorgensen B.
        • Carstensen F.
        • Persson H.L.
        • Gulseth M.
        • Thuresson P.
        • Fenici D.
        • Nathanson T.
        • Nystrom J.W.
        • Eriksson J.
        Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
        Lancet Diabetes Endocrinol. 2017; 5: 709-717
        • Neal B.
        • Perkovic V.
        • Mahaffey K.W.
        • de Zeeuw D.
        • Fulcher G.
        • Erondu N.
        • Shaw W.
        • Law G.
        • Desai M.
        • Matthews D.R.
        Canagliflozin and cardiovascular and renal events in type 2 diabetes.
        N Engl J Med. 2017; 377: 644-–657
        • Zinman B.
        • Wanner C.
        • Lachin J.M.
        • Fitchett D.
        • Bluhmki E.
        • Hantel S.
        • Mattheus M.
        • Devins T.
        • Johansen O.E.
        • Woerle H.J.
        • Broedl U.C.
        • Inzucchi S.E.
        Empagliflozin, Cardiovascular outcomes, and mortalityin type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • NHS
        DESMOND Project.
        2008 (http://www.desmond-project.org.uk/. (Last accessed 13 July 2017))
        • X-PERT Health
        X-PERT Diabetes Course.
        2017 (https://www.xperthealth.org.uk/Courses. (Last accessed 13 July 2017))
        • Holman R.R.
        • Paul S.K.
        • Bethel M.A.
        • Matthews D.R.
        • Neil H.A.
        10-year follow-up of intensive glucose control in type 2 diabetes.
        N Engl J Med. 2008; 359: 1577-1589
        • National Institute of Diabetes and Digestive and Kidney Diseases
        Diabetes Prevention Program (DPP).
        2008 (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp/Documents/DPP_508.pdf. (Last accessed 6 June 2017))
        • World Health Organization
        National Medicines List/Formulary/Standard Treatment Guidelines.
        2017 (http://www.who.int/selection_medicines/country_lists/en/. (Last accessed 4 September 2017))
        • World Health Organization
        Tracking Universal Health Coverage First Global Monitoring Report.
        2015 (http://apps.who.int/iris/bitstream/10665/174536/1/9789241564977_eng.pdf?ua=1. (Last accessed 6 June 2017))
        • Seidu S.
        • Davies M.J.
        • Farooqi A.
        • Khunti K.
        Integrated primary care: is this the solution to the diabetes epidemic?.
        Diabet Med. 2017; 34: 748-750
        • Khunti K.
        • Ganguli S.
        Who looks after people with diabetes: primary or secondary care?.
        J R Soc Med. 2000; 93: 183-186
        • Rao M.
        • Pilot E.
        The missing link—the role of primary care in global health.
        Glob Health Action. 2014; 7: 23693
        • US Department of Veteran Affairs
        VA/DoD Clinical Practice Guidelines: Management of Diabetes Mellitus in Primary Care (2017).
        2017 (https://www.healthquality.va.gov/guidelines/CD/diabetes/. (Last accessed 13 June 2017))
        • Renders G.D.
        • Valk S.
        • Griffin E.H.
        • Wagner J.T.
        Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings.
        Cochrane Database Syst Rev. 2001; : CD001481
        • The King's Fund
        Understanding pressures in general practice.
        2016 (https://www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/Understanding-GP-pressures-Kings-Fund-May-2016.pdf. (Last accessed 13 June 2017))
        • Stark Casagrande S.
        • Fradkin J.E.
        • Saydah S.H.
        • Rust K.F.
        • Cowie C.C.
        The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010.
        Diabetes Care. 2013; 36: 2271-2279
        • Khunti K.
        • Nikolajsen A.
        • Thorsted B.L.
        • Andersen M.
        • Davies M.J.
        • Paul S.K.
        Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
        Diabetes Obes Metab. 2016; 18: 401-409
        • Khunti K.
        • Wolden M.L.
        • Thorsted B.L.
        • Andersen M.
        • Davies M.J.
        Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.
        Diabetes Care. 2013; 36: 3411-3417
        • Polonsky W.H.
        • Henry R.R.
        Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors.
        Patient Prefer Adherence. 2016; 10: 1299-1307
        • Mata-Cases M.
        • Franch-Nadal J.
        • Real M.
        • Lopez-Simarro K.
        • Mauricio D.
        Therapeutic inertia in patients treated with two or more antidiabetics in primary care: factors predicting intensification of treatment.
        Diabetes Obes Metab. 2018; 20: 103-112
        • Joshi D.
        Improving adherence and outcomes in diabetic patients.
        Patient Prefer Adherence. 2017; 11: 271-275
        • Bongaerts B.W.
        • Mussig K.
        • Wens J.
        • Lang C.
        • Schwarz P.
        • Roden M.
        • Rathmann W.
        Effectiveness of chronic care models for the management of type 2 diabetes mellitus in Europe: a systematic review and meta-analysis.
        BMJ Open. 2017; 7e013076
        • Nolte E.
        • Pitchforth E.
        What is the evidence on the economic impacts of integrated care?.
        Copenhagen World Health Org. 2014; 11: 478-488
        • Ouwens H.
        • Wollersheim R.
        • Hermens M.
        Integrated care programmes for chronically ill patients: a review of systematic reviews.
        Int J Qual Health Care. 2005; 17: 141-146
        • Wenzel H.
        • Simmons D.
        An introduction to integrated care and diabetes integrated car.
        in: Simmons D. Wenzel H. Zgibor J.C. Integrated Diabetes Care. Springer International Publishing, Cham, Switzerland2017: 1-9
        • Goulder T.
        • Kar P.
        Facillitating diabetes care — a community approach.
        BMJ Qual Improv Rep. 2013; 2
        • Seidu S.
        • Bodicoat D.H.
        • Davies M.J.
        • Daly H.
        • Stribling B.
        • Farooqi A.
        • Brady E.M.
        • Khunti K.
        Evaluating the impact of an enhanced primary care diabetes service on diabetes outcomes: a before-after study.
        Prim Care Diabetes. 2017; 11: 171-177
        • World Health Organization
        Global Report on Diabetes.
        2016 (http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1. (Last accessed 6 June 2017))
        • Diabetes Canada
        The Canadaian Diabetes Risk Questionnaire.
        2017 (http://www.take2minutes.ca/. (Last accessed 16 June 2017))
        • NHS England
        NHS Diabetes Prevention Programme (NHS DPP).
        2017 (https://www.england.nhs.uk/diabetes/diabetes-prevention/. (Last accessed 4 September 2017))
        • American Diabetes Association
        Stop Diabetes.
        2016 (http://stopdiabetes.com/. (Last accessed 16 June 2017))
        • Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Análise e Situação de Saúde
        Plano de ações estratégicas para o enfrentamento das doenças crônicas não transmissíveis (DCNT) no Brasil, 2011-2022.
        Ministério da Saúde, Brasília2011 (http://bvsms.saude.gov.br/bvs/publicacoes/plano_acoes_enfrent_dcnt_2011.pdf. (Last accessed 4 September 2017))
        • S.S.e.I. Ministerio de Sanidad
        Gobierno de Espana, Estrategia en Diabetes del Sistema Nacional de Salud.
        2012 (http://www.msps.es/organizacion/sns/planCalidadSNS/pdf/excelencia/cuidadospaliativos-diabetes/DIABETES/Estrategia_en_diabetes_del_SNS_Accesible.pdf. (Last accessed 20 December 2017))
        • Costa B.
        • Barrio F.
        • Cabre J.J.
        • Pinol J.L.
        • Cos X.
        • Sole C.
        • Bolibar B.
        • Basora J.
        • Castell C.
        • Sola-Morales O.
        • Salas-Salvado J.
        • Lindstrom J.
        • Tuomilehto J.
        Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention.
        Diabetologia. 2012; 55: 1319-1328
        • Costa B.
        • Castell C.
        • Cos X.
        • Sole C.
        • Mestre S.
        • Canela M.
        • Boquet A.
        • Cabre J.J.
        • Barrio F.
        • Flores-Mateo G.
        • Ferrer-Vidal D.
        • Lindstrom J.
        Rationale and design of the DP-TRANSFERS project: diabetes prevention-transferring findings from European research to society in Catalonia.
        J Transl Med. 2016; 14: 103
        • Knowler W.C.
        • Fowler S.E.
        • Hamman R.F.
        • Christophi C.A.
        • Hoffman H.J.
        • Brenneman A.T.
        • Brown-Friday J.O.
        • Goldberg R.
        • Venditti E.
        • Nathan D.M.
        10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
        Lancet. 2009; 374: 1677-1686
        • Mundet F.
        • Mata-Cases P.
        • Roura J.
        • Franch M.
        • Birules R.
        • Gimbert J.
        • Cos X.
        Trends in chronic complications of type 2 diabetic patients from Spanish primary health care centres (GEDAPS study): ten year-implementation of St. Vincent recommendations.
        Prim Care Diabetes. 2012; 6: 11-18
        • Chinese Center for Disease Control and Prevention
        China National Plan for NCD Prevention and Treatment (2012-2015).
        2012 (http://www.chinacdc.cn/en/ne/201207/t20120725_64430.html. (Last accessed 6 June 2017))
        • South African Ministry of Health
        Strategic Plan for the Prevention and Control of Non-Communicable Diseases 2013–17.
        2013 (http://www.hsrc.ac.za/uploads/pageContent/3893/NCDs%20STRAT%20PLAN%20%20CONTENT%208%20april%20proof.pdf. (Last accessed 6 June 2017))
        • NHS
        What is the DESMOND Programme?.
        2017 (http://www.desmond-project.org.uk/whatisthedesmondprogramme-271.html. (Last accessed 4 September 2017))